Health · 1 sources covering this

STAT+: In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs

AstraZeneca detailed the surprise failure of a closely watched heart disease trial, a study with ripple effects for a competitive billion-dollar market.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·1h ago
STAT+: In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs
AstraZeneca detailed the surprise failure of a closely watched heart disease trial, a study with ripple effects for a competitive billion-dollar market.
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/0836a00e91a0d5f852f470251467e4d2bded7be4"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs"></iframe>

STAT+: In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs

How 1 sources are covering this

STAT+: In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs

More from Health

Can't stop fixating on the way you look? These 4 mental exercises may help

Why Older Pedestrians Fare Worse in Car Crashes

High Fertility Costs Push Americans Abroad for IVF Treatment

Trump and Kennedy’s Health Industry Deals Haven’t Been Enforced and Are at Risk of Vanishing

Reader

Trust & legal

Across the network